Table Info

Table 4.

Ongoing clinical trials in ARID1A-mutated cancers

Clinical trial number	Phase	Randomization	Disease	Setting	Experimental arm	Control arm	Primary objective	Status
NCT05023655	2	No	Solid tumor	Advanced	Tazemetostat	NA	ORR	Recruiting
NCT04284202	2	No	NSCLC	Advanced	PD-1 + dasatinib	NA	PFS	Unknown
NCT04065269	2	No	Ovarian and endometrial clear cell carcinoma	Advanced	AZD6738 +/– olaparib	NA	ORR	Recruiting
NCT04953104	2	No	Urothelial cancer	Advanced	Nivolumab	NA	ORR	Not yet recruiting
NCT04957615	2	No	Solid tumor	Advanced	Nivolumab	NA	ORR	Recruiting
NCT05154994	1	No	Urothelial cancer	Advanced	Tremelimumab + durvalumab + belinostat	NA	RP2D	Recruiting
NCT04633902	2	No	Melanoma	Advanced	Olaparib + pembrolizumab	NA	ORR	Recruiting
NCT03682289	2	No	Solid tumor	Advanced	AZD6738 +/– olaparib	NA	ORR	Recruiting
NCT02576444	2	No	Solid tumor	Advanced	AZD5363 + olaparib	NA	ORR	Active, not recruiting
NCT05379972	2	No	Gastric cancer	Advanced	Pembrolizumab + olaparib + SBRT	NA	ORR	Not yet recruiting
NCT03207347	2	No	Solid tumor	Advanced	Niraparib	NA	ORR	Active, not recruiting
NCT04042831	2	No	Biliary tract cancer	Advanced	Olaparib	NA	ORR	Recruiting
NCT04104776	1-2	No	Solid tumor, lymphoma	Advanced	CPI-0209	NA	DLTs; ORR	Recruiting

ORR: overall response rate; NSCLC: non-small cell lung cancer; PD-1: programmed death-1; RP2D: recommended phase 2 dose; SBRT: stereotactic body radiation therapy; AZD6738: ceralasertib; CPI-0209: tulmimetostat; DLTs: dose-limiting toxicities

Declarations

Author contributions

RF: Conceptualization, Formal analysis, Data curation, Writing—review & editing. GD: Conceptualization, Supervision. MF and PL: Data curation. VA and FPS: Formal analysis. GS: Supervision. All authors read and approved the submitted version.

Conflicts of interest

RF, MF, PL, VA, and FPS declare that they have no conflicts of interest. GS has served on advisory boards for TESARO Bio Italy S.r.l, Johnson & Johnson, Clovis Oncology Italy S.r.l. He received support for travel or accommodation from MSD Italy S.r.l and Clovis Oncology Italy S.r.l. GD has served on advisory board of Beigene and received support for travel and accommodation from Roche.

Ethical approval

The study complies with the declaration of Helsinki and was approved by the Ethics Committee of Fondazione Policlinico Universitario A. Gemelli IRCCS (ID5261).

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The data generated in the present study can be requested from the corresponding author (Gennaro Daniele, gennaro.daniele@policlinicogemelli.it).

Funding

Not applicable.

Copyright

References

Mathur R. ARID1A loss in cancer: towards a mechanistic understanding. Pharmacol Ther. 2018;190:15–23. [DOI] [PubMed]

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013;26:1525–35. [DOI] [PubMed]

Inoue H, Furukawa T, Giannakopoulos S, Zhou S, King DS, Tanese N. Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors. J Biol Chem. 2002;277:41674–85. [DOI] [PubMed]

Wilsker D, Patsialou A, Zumbrun SD, Kim S, Chen Y, Dallas PB, et al. The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexes. Nucleic Acids Res. 2004;32:1345–53. [DOI] [PubMed] [PMC]

Mandal J, Mandal P, Wang TL, Shih IM. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29:71. [DOI] [PubMed] [PMC]

Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228–31. [DOI] [PubMed] [PMC]

Luo Q, Wu X, Chang W, Zhao P, Zhu X, Chen H, et al. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression. Cancer Res. 2020;80:406–17. Erratum in: Cancer Res. 2020;80:4302. [DOI] [PubMed]

Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287. [DOI] [PubMed]

Jiang T, Chen X, Su C, Ren S, Zhou C. Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes. J Cancer. 2020;11:776–80. [DOI] [PubMed] [PMC]

10.

Khosrowjerdi SJ, Horick NK, Clark JW, Parikh AR, Allen JN, Nipp RD, et al. Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: duration of response to platinum-based chemotherapy. J Clin Oncol. 2021;39:e15611. [DOI]

11.

Kato MK, Yoshida H, Tanase Y, Uno M, Ishikawa M, Kato T. Loss of ARID1A expression as a favorable prognostic factor in early-stage grade 3 endometrioid endometrial carcinoma patients. Pathol Oncol Res. 2021;27:598550. [DOI] [PubMed] [PMC]

12.

Wang X, Che K, Shi T, Liu Q, Xu X, Wu H, et al. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer. J Cancer Res Clin Oncol. 2022;148:1583–95. [DOI] [PubMed]

13.

Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, et al. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget. 2015;6:39088–97. [DOI] [PubMed] [PMC]

14.

Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020;8:e000438. [DOI] [PubMed] [PMC]

15.

Wang N, Qin Y, Du F, Wang X, Song C. Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: a systematic review and meta-analysis. Gene. 2022;834:146638. [DOI] [PubMed]

16.

Daniel Ampanattu S, Ahmed G, Thapa B, Janardan A, Vallejos A, Taylor B, et al. Predictive impact of ARID1A status in solid tumors. Eur J Cancer. 2022;174:S96. [DOI]

17.

Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5:752–67. [DOI] [PubMed] [PMC]

18.

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837. [DOI] [PubMed] [PMC]

19.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31. [DOI] [PubMed] [PMC]

20.

ClinicalTrials.gov [Internet]. [cited 2023 Feb 2]. Available from: https://clinicaltrials.gov

21.

Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021;31:1471–5. [DOI] [PubMed] [PMC]

22.

Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, et al. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst. 2014;106:dju146. [DOI] [PubMed] [PMC]

23.

Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget. 2014;5:5295–303. [DOI] [PubMed] [PMC]

24.

Kurzrock R, Aggarwal C, Weipert C, Kiedrowski L, Riess J, Lenz HJ, et al. Prevalence of ARID1A mutations in cell-free circulating tumor DNA in a cohort of 71,301 patients and association with driver co-alterations. Cancers (Basel). 2022;14:4281. [DOI] [PubMed] [PMC]

25.

Chaluts D, Dullea JT, Ali M, Vasan V, Devarajan A, Rutland JW, et al. ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas. J Cancer Res Clin Oncol. 2023;149:5165–72. [DOI] [PubMed]